Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma – Authors' reply

Importantly, the CROSS trial recruited a minority (23%) of patients with oesophageal squamous cell cancer, of whom 49% had a complete pathological response following neoadjuvant therapy, which is likely to have contributed substantially to the R0 resection rate in that study.2 The recently published genomic characterisation of oesophageal cancer in The Cancer Genome Atlas shows that oesophageal squamous cell cancer and adenocarcinoma are completely distinct disease entities; therefore, comparison of the results of trials containing...